Meet Dr. Robert G. Szewc, M.D. FASN
Board Certified in Nephrology – Interventional Nephrologist Internal Medicine
Dr. Robert’s Szewc (Chefs) mission is to provide the best kidney care possible and to preserve, maintain, or reverse kidney failure.
“It is beyond my passion to be able to assist patients through the difficult journey of kidney transplant and educate the patients and their families about their disease through a holistic and conventional approach.“
Dr. Robert G. Szewc Mission
Dr. Robert’s Szewc (Chefs) mission and life work are dedicated to preserving the longevity of the kidneys. Focusing on preventative care and patient education empowers patients and their families to improve their health and quality of life.
He is highly dedicated to educating medical students and policymakers about the importance of kidney health and its effects on our community and healthcare system.
Dr. Szewc (Chefs) has been a Nephrologist for 25 years, serving my patients in the San Antonio community. The goal of the care I provide is to be able to preserve, maintain or even reverse kidney failure. To be able to assist patients through the difficult journey to kidney transplant and to be able to educate patients and families about their disease through a holistic and conventional approach. It is beyond my passion; it is personal to be able to help every single patient and design a treatment plan which fits the individual needs. I strive to preserve the longevity of the kidneys by focusing on lifestyle modifications and preventative care as essential factors of the whole treatment plan.
Texas Medical License: L2686
Dr. Robert G. Szewc, Life of Work
Work Experience
2002 - Present
CEO & Founder
Kidney Hypertension Transplant Specialists, San Antonio, TX
2016 - Present
CEO & Founder
Innovative Dialysis Solutions,
Bulverde, TX
2017 - Present
CEO & Founder
Innovative Dialysis Solutions,
Devine, TX
Professional Training
1993 - 1994
Assistant Professor
Department of Medicine Nephrology, San Antonio, TX
1998 - 1999
Internal Medicine Residency
Chief Resident
UMass Memorial Healthcare
Worcester, MA
2001 - 2002
Chief Nephrology Fellow
UTHSCSA
San Antonio, TX
2007 - 2009
Internal Medicine Internship
City Hospital,
Poland
Recognition Awards
1998 - 1999
- UMass Memorial Resident Teaching Award
2003
-
The University of Texas Attending Physician
2010
- ESRD Fistula First Benchmark Facility Award
- ERSD Network of Texas Superior Performance in Hemodialysis
- Serum Albumin Management
- ESRD Network of Texas Hemodialysis Adequacy Management
2016
- America’s Best Physicians
2017
- Who’s Who Top Doctor
2019
- Top Doctor- Top Nephrologist
2020
- Top Nephrologist
Certifications
Board Certified in Internal Medicine 1999
ACLS Certification 2001
Board Certified in Nephrology 2001 and 2019
ECFMG Certificate 1993
Professional Education
Graduated 11/1991 M.D.- Medical School of Lublin Lublin, Poland
Licenses
Medical License in Texas L.2686
Polish License to Practice Medicine - 1993
Board Certified in Nephrology- 2001 & 2019
Board Certified in Internal Medicine- 1999
ACLS Certification- 2001
ECFMG Certification- 1993
Expertise
Languages
- Chronic Kidney Disease
- Hypertension
- Obesity and
- Chronic metabolic problem management through personalized treatment plans consisting of dietary counseling and lifestyle modification is crucial, along with the newest achievements of medical practice. Promoting home modalities of renal replacement therapy as a bridge to kidney transplant.
- English
- Polish
- Russian
- Medical Spanish
PROFESSIONAL EXPERIENCE
Cuero Lakeview Kidney Center
2004 to 2006
Cuero Lakeview Kidney Center: Cuero TX
Medical Director
Provide medical director oversight regarding clinic operation, patient safety, and patient quality outcomes at the chronic hemo-dialysis program; led the ongoing development of Standard Operating Procedures for the dialysis programs and ongoing Quality Assessment and Process Improvement activities.
Barlite Southwest Kidney Center
2004 to Present
Barlite Southwest Kidney Center: San Antonio TX
Medical Director
Provide medical director oversight regarding clinic operation, patient safety, and patient quality outcomes at the chronic hemo-dialysis program, peritoneal dialysis program and home-hemo dialysis; led the ongoing development of Standard Operating Procedures for the dialysis programs and ongoing Quality Assessment and Process Improvement activities.
San Saba Downtown Kidney Center
2004 to Present
San Saba Downtown Kidney Center: San Antonio
Medical Director
Provide medical director oversight regarding clinic operation, patient safety, and patient quality outcomes at the chronic hemo-dialysis program; led the ongoing development of Standard Operating
Procedures for the dialysis programs and ongoing Quality Assessment and Process Improvement activities.
HOSPITAL APPOINTMENTS
Southwest General Hospital • San Antonio, TX
July 2013
Ethics Committee Chairman
Southwest General Hospital • San Antonio, TX
June 2009 – June 2011
Health Information Management Committee
Southwest General Hospital • San Antonio, TX
June 2011 – June 2013
Pharmacy Theraputic Committee Chairman
Texas Vista Medical Center • San Antonio, TX
July 2018
Director of Acute Dialysis
RESEARCH EXPERIENCE
LIFEVEST
LIFEVEST – Wearable Cardioverter Defibrillator in Hemodialysis Patients (WED_HED) Study.
Sponsor: ZOLL, Sub-Principal Investigator: Robert G. Szewc, MD, 03/15.
ROXADUSTAT
ROXADUSTAT – A Phase 3, Multicenter, Randomized, Double–Blind, Placebo–Controlled Study Evaluating the Safety and Efficacy of XX-XXX for the Treatment of Anemia in Chronic Disease Patients not on Dialysis.
Sponsor: AstraZeneca, Principal Investigator: Robert G. Szewc, MD. 11/14
PHOSPHATE
PHOSPHATE – A Multicenter, Double – Blind Placebo – Controlled Randomized Study to Evaluate the Efficacy and Safety of XX-XXX in Subjects with Hyperphosphatemia and Dialysis – Dependent Chronic Disease.
Sponsor: Phosphate Therapeutics Ltd. (PTL) Principal Investigator: Robert G. Szewc, MD 04/14
AGMEN
AGMEN – A Randomized, Double – Blind, Placebo Controlled Study to Assess the Efficiency and Safety of Cinacalcet HCL in Chronic Kidney Disease Subjects with Secondary Hyperparathyroidism not Receiving Dialysis (Protocol 20000178.) Sub – Principal Investigator: Robert G. Szewc, MD 2005 – 2006
ABBOTT
ABBOTT – A Phase III, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Multi-Center Study to Evaluate the Safety and Efficacy of Zemplar Capsule in reducing Serum Intact Parathyroid Levels in Chronic Kidney Disease Stage V Subjects in Hemodialysis or Peritoneal Dialysis (Protocol M03-635) Sub-Principal Investigator: Robert G. Szewc, MD 2004-2005.
AMGEN INC
AMGEN INC – A Placebo-Controlled, Double-Blinded, Multicenter Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of Chronic Kidney Disease (Hemodialysis and Peritoneal Dialysis) (Protocol 20000188.) Sub-Principal Investigator: Robert G Szewc, MD 2002-2003.
NATIONAL INSTITUTE OF HEALTH
NIH – Family Investigation of Nephrology in Diabetes (FIND) 2002-2003
PATIROMER
PATIROMER – The Effect of Food: An Open – Labeled, Randomized, Parallel Group Phase 4 Study of the Efficacy and Safety of Patiromer for Oral Suspension with or without food for the treatment of Hyperkalemia (TOURMALINE.) Sub- Principal Investigator: Robert G. Szewc, MD, 03/15
NABI PHARMACEUTICALS, INC – A Phase III, Multicenter, Randomized, Placebo- Controlled, Double – Blinded Study to Evaluate Efficacy of Staph V AX, a Blvalent Staphylococcus Eureus Glycocanjugate Vaccine In Adults on Hemodialysis (Protocol 1371) Sub-principal Investigator: Robert G Szewc, MD 2004-2005
AMGEN INC – A Placebo-Controlled, Double-Blinded, Multicenter Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of Chronic Kidney Disease (Hemodialysis and Peritoneal Dialysis) (Protocol 20000188.) Sub-Principal Investigator: Robert G Szewc, MD 2002-2003.
ABBOTT LABORATORIES INC. – A Phase III, Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Study to Evaluate the Safety and Efficacy of Zemplar Capsule (Dosed Three Times Weekly) in reducing Elevated Serum Intact Parathyroid Hormone Levels in Subject with Chronic Kidney Disease (Protocol 2001020). Principal Investigator: Robert G. Szewc MD 2002-2003
NIH – Family Investigation of Nephrology in Diabetes (FIND) 2002-2003
ABBOT LABORATORIES INC. – A Phase III, Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety of Xemplar Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Hemodialysis (Protocol 2001-013)
Principal Investigator: Robert G Szewc 2002-2003
KERYX
KERYX – A Phase 3 Study of XX-XXX for the treatment of Iron Deficiency Anemia in Adult Subject with Non-Dialysis Dependent Chronic Kidney Disease.
Sponsor: Keryx Biopharmaceuticals, Principal Investigator: Robert G. Szewc 09/14
SHIRE
SHIRE – A Phase IV, Open- Label, Multi- Center Trial Evaluation the Efficacy of Fosrenal (Lanthum Carbonate) Compared to Existing Therapy in Adults with End Stage Renal Disease Treated for Hyperphosphatemia, (Protocol SPD 405 – 401) Principal Investigator: Robert G. Szewc, MD 2005 – 2006
ABBOTT LABORATORIES, INC
ABBOTT LABORATORIES, INC – A Phase IV, Prospective, Randomized, Active – Controlled, Double- Blind, Double – Dummy, Multi – Center study to Evaluate the Survival Benefits of Zemplar Relative to Calcilex in Subjects with Stave V Chronic Kidney Disease on Hemodialysis. (Protocol M02 – 516) Sub – Principal
Investigator: Robert G. Szewc, MD. 2003 – 2004
NABI PHARMACEUTICALS, INC
NABI PHARMACEUTICALS, INC – A Phase III, Multicenter, Randomized, Placebo- Controlled, Double – Blinded Study to Evaluate Efficacy of Staph V AX, a Blvalent Staphylococcus Eureus Glycocanjugate Vaccine In Adults on Hemodialysis (Protocol 1371) Sub-principal Investigator: Robert G Szewc, MD 2004-2005
ABBOTT LABORATORIES INC
ABBOTT LABORATORIES INC. – A Phase III, Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Zemplar Capsule (Dosed Three Times Weekly) in reducing Elevated Serum Intact Parathyroid Hormone Levels in Subject with Chronic Kidney Disease (Protocol 2001020). Principal Investigator: Robert G. Szewc MD 2002-2003
ABBOT LABORATORIES INC
ABBOT LABORATORIES INC. – A Phase III, Prospective, Randomized, Placebo-Controlled, Double- Blind, Multicenter, Study to Evaluate the Safety of Xemplar Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Hemodialysis (Protocol 2001-013)
Principal Investigator: Robert G Szewc 2002-2003
PUBLICATIONS
Treatment of Symptomatic Coronary Artery Disease in Patients with End-Stage Renal Disease on Hemodialysis with Paclitaxel-eluting TAXUS Stent
Treatment of Symptomatic Coronary Artery Disease in Patients with End-Stage Renal Disease on Hemodialysis with Paclitaxel-eluting TAXUS Stent. Szymon L Wiernek, R. Stefan Jiesz, Barbara K. Wiernek, Portr P. Buzman, Adam Janas, Jack L. Martin, Blazej Trela, Robert G. Szewc, Pawel E Buszman. Hemodialysis International 2015;19:402-411.
Plaque Excision Below the Knee for Limb Salvage in Patients with End Stage Renal Disease and Diabetes
Plaque Excision Below the Knee for Limb Salvage in Patients with End Stage Renal Disease and Diabetes. R.S. Kiesz, P. Buszman, M.A. Walker, R.G.Szewc, M.W. McQueen, San Antonio Endovascular and Heart Institue; Silesian Medical School, Katowice, Poland; Catheterization and Cardiovascular Interventions. 2006 May; 67 (5): 755. Also to be published in European Heart Journal 2006.
Renal Stenting with Distal Embolization Protection Prospective Registry; Preliminary Experience
Renal Stenting with Distal Embolization Protection Prospective Registry; Preliminary Experience, R.S. Kiesx, R. Szewc, T. Ybarra, M. Walker. San Antonio Endovascular and Heart Institute, San Antonio, Texas, Catheterization and Cardiovascular Interventions. 2005 May; 65(1): 152.
Prediction of GFR in Liver Transplant Candidates
Prediction of GFR in Liver Transplant Candidates. Skluzacek PA, R.G. Szwec, Nolan CR 3rd Riley DJ, Lee S, Pergola PE. Department of Medicine, Wilford Ha; Medical Center, Lackland Air Force Base, San Antonio, Texas; Am J Kidney Dis. 2003 Dec. 42(6); 1169-76